U.S. Markets closed

Titan Pharmaceuticals, Inc. (TTNP)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.00+0.05 (+2.56%)
At close: 3:59PM EDT
People also watch
VNDABDSIIMUCONCSNAVB

Titan Pharmaceuticals, Inc.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States
650-244-4990
http://www.titanpharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedAge
Dr. Marc Rubin M.D.Exec. Chairman368kN/A62
Mr. Sunil Bhonsle M.B.A.CEO, Pres, Principal Financial Officer, Sec. & Director491kN/A67
Dr. Katherine L. Beebe Ph.D.Chief Devel. Officer and Exec. VPN/AN/AN/A
Brian E. CrowleyVP of Fin.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson’s disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

Corporate Governance

Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.